Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

Open single-group treatment study administering a single IV infusion of ketamine 0.5 mg/kg to participants with treatment-resistant depression (n=20).

Outcomes include clinical response in depression and mechanistic measures: glutamate neurotransmission by magnetic resonance spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).